Home > Urology > EAU 2020 > PSMA PET-CT staging is 27% more accurate

PSMA PET-CT staging is 27% more accurate

Labelled prostate-specific membrane antigen (PSMA) in PET-CT fusion (PSMA PET-CT) was superior in specificity and sensitivity to conventional imaging in pre-treatment staging of intermediate- and high-risk localised prostate cancer.

Prof. Michael Hofman (Peter MacCallum Cancer Centre, Australia) presented the results of the ProPSMA study, which was recently also published in The Lancet [1,2]. The rationale of the study was that pre-treatment staging of intermediate- and high-risk localised prostate cancer is important for treatment choice, yet current standard imaging has limited sensitivity. The study investigated whether imaging using PSMA PET-CT was superior to conventional imaging in pre-treatment staging.

Men with histologically confirmed prostate cancer who were being considered for curative-intent radical prostatectomy or radiotherapy (n=302) were randomly alloc...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on